In the randomized 80-patient study, the observed median overall survival was 5.2 months for patients who received a combination of Zybrestat and chemotherapy compared with four months for patients receiving chemotherapy alone, indicating a 27 percent reduction in the risk of death

In that trial, patients receiving Eylea at an initial dose of 2 mg, followed by treatment on an as-needed basis, had a mean improvement in best-corrected visual acuity from baseline at week 24 of 12...1 letters, compared to a loss of 2 letters in patients receiving sham injections (p < 0.0001

Rockwell Medical Inc., of Wixom, Mich., said its CRUISE-1 Phase III efficacy study for SFP, an investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis, has completed patient dosing

The primary objective of TRAVERSE is to determine overall survival for patients receiving Pexa-Vec plus best supportive care vs

The trial design was supported by promising data from a Phase IIb study in patients receiving bavituximab plus docetaxel

The findings suggested that RAS mutation status beyond KRAS may be predictive of negative outcomes in patients receiving Vectibix plus Folfox in mCRC

The mean change in hemoglobin in ferumoxytol-treated AUB patients was 2.8 g/dL, compared to no increase (0 g/dL) in AUB patients receiving placebo (p < 0.0001

In a sub-study, mean saliva production in patients receiving Tolenix was restored to a level similar to that of placebo

Results showed that patients receiving Sufentanil NanoTabs realized a significantly greater SPID-48 during the study period than placebo-treated patients (p = 0.001

Avaxia plans to enroll 24 patients in three dose groups, with six patients receiving the study drug and two patients receiving placebo in each dose group, for 28 days

Patients receiving either 1,000-mg or 2,000-mg daily doses of GTx-758 demonstrated significant reductions in their serum-free (unbound) testosterone levels, with related reductions in their levels of serum prostatic specific antigen

Amgen Inc., of Thousand Oaks, Calif., reported results from the Pegfilgrastim and anti-VEGF evaluation study (PAVES), a Phase III trial, which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for first-line treatment of locally advanced or metastatic colorectal cancer...The incidence of grade 3 or 4 febrile neutropenia in patients receiving Neulasta across the first four cycles of chemotherapy was 2.4 percent compared to 5.7 percent in the placebo group

Immunovaccine Inc., of Halifax, Nova Scotia, reported results from a Phase I study showing that all ovarian cancer patients receiving cancer vaccine DPX-Survivac who were evaluable by tetramer staining produced survivin-specific CD8 T cells following one or two vaccinations...All patients receiving DPX-Survivac also demonstrated antigen-specific immune responses, as measured by at least one of the study's three immune monitoring assays

iCo Therapeutics Inc., of Vancouver, British Columbia, said there have been no drug-related serious adverse events among patients receiving repeat doses of iCo-007 at the midpoint of its Phase II iDEAL study in diabetic macular edema

Patients receiving Tolenix, a twice-daily combination of muscarinic antagonist tolterodine and muscarinic agonist pilocarpine, exhibited no safety issues and also demonstrated statistically significant and clinically meaningful improvements in their saliva production and dry mouth side effects, as compared to Detrol

Data showed that 82.3 percent of patients who received oritavancin met the early clinical endpoint of cessation of spread, absence of fever and no rescue antibiotics, compared to 78.9 percent of patients receiving vancomycin

In beta-SPECIFIC 2, 45 percent of patients receiving ACZ885 who were taking corticosteriods at the beginning of the study were able to reduce the dosage substantially, and one-third of patients discontinued steriods

The second Phase III trial resulted in a median two-year progression-free survival rate of 92 percent in patients with diffuse large B-cell lymphoma who received maintenance lenalidomide, compared with 83 percent for patients receiving lenalidomide plus Rituxan (rituximab, Biogen Idec Inc. and Roche AG

All patients receiving sofosbuvir/RBV became HCV RNA negative on treatment and relapse accounted for all virologic failures